SEOM clinical guideline on hereditary colorectal cancer (2019)

C. Guillén-Ponce, E. Lastra, I. Lorenzo-Lorenzo, T. Martín Gómez, R. Morales Chamorro, A. B. Sánchez-Heras, R. Serrano, M. C. Soriano Rodríguez, J. L. Soto, L. Robles

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

© 2020, The Author(s). In the last 2 decades, clinical genetics on hereditary colorectal syndromes has shifted from just a molecular characterization of the different syndromes to the estimation of the individual risk of cancer and appropriate risk reduction strategies. In the last years, new specific therapies for some subgroups of patients have emerged as very effective alternatives. At the same time, germline multigene panel testing by next-generation sequencing (NGS) technology has become the new gold standard for molecular genetics.
Original languageAmerican English
Pages (from-to)201-212
Number of pages12
JournalClinical and Translational Oncology
DOIs
StatePublished - 1 Feb 2020
Externally publishedYes

Fingerprint Dive into the research topics of 'SEOM clinical guideline on hereditary colorectal cancer (2019)'. Together they form a unique fingerprint.

  • Cite this

    Guillén-Ponce, C., Lastra, E., Lorenzo-Lorenzo, I., Martín Gómez, T., Morales Chamorro, R., Sánchez-Heras, A. B., Serrano, R., Soriano Rodríguez, M. C., Soto, J. L., & Robles, L. (2020). SEOM clinical guideline on hereditary colorectal cancer (2019). Clinical and Translational Oncology, 201-212. https://doi.org/10.1007/s12094-019-02272-y